Fritextsökning
Innehållstyper
-
Den enes snor blir den andres bot
Snortransplantation – ordet ger rysningar. Nu presenteras en studie där skånska patienter med kronisk tjock snuva, förbättrades efter att ha använt nässprej inn...
-
Källor: FDA:s vaccinchef tvingas bort – riktar skarp kritik mot Kennedy
Vaccinchefen vid FDA lämnar sin post och kritiserar samtidigt landets hälsominister för att ha låtit ”desinformation och lögner” styra hans tankar om vacciners säkerhet.
-
From lab to patient – the art of developing new antibody therapies
For 25 years, Danish company Genmab has been developing antibodies and has managed to get several drugs all the way to the patient. Esther Breij has been along ...
-
The US is leaving the WHO
The newly installed US President, Donald Trump, has issued an executive order for the US to leave the World Health Organization, WHO.
-
Compact and leak-tight powerhouse
Media-separated solenoid valve VYKA from Festo is virtually leak-free
-
From powder to implant
Quality assurance for additively manufactured implants.
-
Quality Assurance for the Highest Medical Standards
Metrology Solutions for Medical Components.
-
FDA godkänner första icke-opioida smärtstillaren på över 20 år
För första gången på flera decennier har en ny typ av läkemedel mot akut smärta som inte är en opioid godkänts i USA.
-
Her company is developing a new tablet form obesity drug
Obesity and diabetes are the primary targets of a new tablet treatment under development by Malmö-based Pila Pharma. The company’s ambition is to take on the bi...
-
Automated nitrogen analysis reduces costs per sample
N-Realizer analytical system from C. Gerhardt increases productivity with valve block from Festo
-
Mastering Urine Microscopy
On-demand Webinar: Microscopy in urinalysis.
-
Ännu ett Alzheimerläkemedel godkänt – lecanemab får konkurrens
Eli Lillys läkemedel donanemab mot Alzheimers godkändes på tisdagen av den amerikanska läkemedelsmyndigheten FDA. Det är det andra godkända bromsläkemedlet mot ...
-
Sobi announces agreement with Enable Injections
Swedish biopharma Sobi has entered into an international development and distribution agreement with US drug delivery company Enable Injections.
-
Government apoints new experts to medicine and health council
Johanna Fälting, Head of Research at BioArctic, and physician Markus Lingman have been appointed as new members of the Swedish Research Council’s Subject Counci...
-
H-index etablerat men ifrågasatt – ”Mäter inte originalitet”
H-index spelar en erkänd roll. Men att stirra sig blind på den siffran kan göra att man missar andra viktiga forskare och genombrott, menar Forska Sveriges gene...
-
MSD discontinues two Keytruda trials
MSD has stopped two late-stage trials that tested its blockbuster immunotherapy Keytruda as a treatment for skin and lung cancer.
-
SupraCube - In life Science
Superconductors must be permanently kept below their transition temperature for levitation. Because of the integrated cooler, applications with superconductors ...
-
Samuel Lagercrantz: ”Är det de sämsta biotechbolagen som går under? Eller finns andra faktorer?”
Icellate Medical, Calmark Sweden, Redwood Pharma, Medfield Diagnostics, Coala Life, Cline Scientific och Ectin Research. Listan med life science-företag som gåt...
-
He takes over the chairmanship of Karolinska Development
Ben Toogood is appointed as the new chairman of Karolinska Developments.
-
Scale Up Your Image Analysis
ZEISS arivis Hub for accelerated analysis and faster results.
-
Anna Törner: Yes, I Am Sick, But Not Weak
”People often say that someone who is ill only has one wish—to get better. But I think that is not true. Someone who is ill also longs to be understood, to be r...
-
Japanese pharma to buy US drugmaker for $2.4 bln
Japanese Ono Pharmaceutical buys the American cancer drug developer Deciphera Pharmaceuticals in one of the largest acquisitions in the industry so far this year.
-
Takeover bid is being completed – Japanese company acquires Calliditas
Japanese company Asahi Kasei completes the bid for Calliditas Therapeutics after reaching over 90 percent of the shareholding. Callidita's board has now decided...
-
Ingrid Lönnstedt: ”The confidence interval and its width”
Always keep an eye on the width of your and others’ confidence intervals, writes Ingrid Lönnstedt in a science column.